{"organizations": [], "uuid": "190725bfddc61765b8e524341fd7be5892f5bd96", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180306.html", "section_title": "Archive News &amp; Video for Tuesday, 06 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ligand-pharma-to-receive-total-pot/brief-ligand-pharma-to-receive-total-potential-license-milestone-payments-of-up-to-533-8-mln-per-agreement-with-roivant-idUSFWN1QO0QA", "country": "US", "domain_rank": 408, "title": "BRIEF-Ligand Pharma To Receive Total Potential License & Milestone Payments Of Up To $533.8 Mln, Per Agreement With Roivant", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.898, "site_type": "news", "published": "2018-03-07T05:59:00.000+02:00", "replies_count": 0, "uuid": "190725bfddc61765b8e524341fd7be5892f5bd96"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ligand-pharma-to-receive-total-pot/brief-ligand-pharma-to-receive-total-potential-license-milestone-payments-of-up-to-533-8-mln-per-agreement-with-roivant-idUSFWN1QO0QA", "ord_in_thread": 0, "title": "BRIEF-Ligand Pharma To Receive Total Potential License & Milestone Payments Of Up To $533.8 Mln, Per Agreement With Roivant", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-ligand pharma to receive total potential license & milestone", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "ligand pharmaceuticals", "sentiment": "negative"}, {"name": "ligand pharmaceuticals inc", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 6 (Reuters) - Ligand Pharmaceuticals Inc:\n* LIGAND PHARMACEUTICALS - PER TERMS OF LICENSE AGREEMENT WITH ROIVANT, CO TO RECEIVE TOTAL POTENTIAL LICENSE & MILESTONE PAYMENTS OF UP TO $533.8 MILLION\n* LIGAND PHARMACEUTICALS SAYS NOW ANTICIPATES 2018 TOTAL REVENUE TO BE APPROXIMATELY $184 MILLION - SEC FILING Source text: ( bit.ly/2FuuOFX ) Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "http://bit.ly/2FuuOFX"], "published": "2018-03-07T05:59:00.000+02:00", "crawled": "2018-03-07T19:20:33.025+02:00", "highlightTitle": ""}